Family Medicine Doctors in Dayton, TX Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Dr. John W Macdonald, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 202 North Church Street, Dayton, TX 77535 Phone: 936-258-2634 Fax: 936-258-7304 |
Dr. Pedro P. Talosig, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 402 S Winfree St, Dayton, TX 77535 Phone: 936-258-2426 Fax: 936-258-2488 |
Dr. Satiskumar P Patel, M.D. MBCHB Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 108 N Main St, Dayton, TX 77535 Phone: 936-258-4920 Fax: 936-258-4927 |
News Archive
Vasovagal syncope - most common emergency situation in the dental office
You see it in movies or while viewing your favorite sitcom; a scene at the doctor's office where the character inevitably gets a little woozy which leads to a fainting spell.
Thesis examines infections caused by Anaplasma phagocytophilum in lambs
Erik Georg Granquist's thesis examines infections caused by the bacterium Anaplasma phagocytophilum in lambs. This bacterium is the cause of the disease tick-borne fever in ruminants and granulocytic anaplasmosis in humans. The bacterium is transmitted by ticks and is the indirect cause of considerable animal welfare problems and financial losses in Norwegian sheep farming.
USPTO issues Notice of Allowance for patent application related to Neogenix Oncology's 16C3 antibody
Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody.
Poster presentation at MASCC Conference summarizes MuGard clinical experience
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, is presenting a scientific poster today at the Multinational Association of Supportive Care in Cancer Conference in Vancouver, B.C. The poster presentation, co-authored by Dr. David Nowotnik of Access Pharmaceuticals and Dr. Caroline Dumas of SpePharm Holdings, summarizes MuGard clinical experience from cancer patients globally undergoing radiotherapy and/or chemotherapy.
› Verified 4 days ago